RATIONALE: Rapid-response impulsivity, characterized by inability to withhold response to a stimulus until it is adequately appraised, is associated with risky behavior and may be increased in a state-dependent manner by norepinephrine. OBJECTIVE: We assessed effects of yohimbine, which increases norepinephrine release by blocking alpha-2 noradrenergic receptors, on plasma catecholamine metabolites, blood pressure, subjective symptoms, and laboratory-measured rapid-response impulsivity. METHODS:Subjects were 23 healthy controls recruited from the community, with normal physical examination and ECG, and negative history for hypertension, cardiovascular illness, and axis I or II disorder. Blood pressure, pulse, and behavioral measures were obtained before and periodically after 0.4 mg/kg oral yohimbine or placebo in a randomized, counterbalanced design. Metabolites of norepinephrine [3-methoxy-4-hydroxyphenylglycol (MHPG) and vanillylmandelic acid (VMA)] and dopamine [homovanillic acid (HVA)] were measured by high-pressure liquid chromatography with electrochemical detection. Rapid-response impulsivity was measured by commission errors and reaction times on the immediate memory task (IMT), a continuous performance test designed to measure impulsivity and attention. RESULTS:Yohimbine increased plasma MHPG and VMA but not HVA. Yohimbine increased systolic and diastolic blood pressure and pulse rate. On the IMT, yohimbine increased impulsive errors and impulsive response bias and accelerated reaction times. Yohimbine-associated increase in plasma MHPG correlated with increased impulsive response rates. Time courses varied; effects on blood pressure generally preceded those on metabolites and test performance. CONCLUSIONS: These effects are consistent with increased rapid-response impulsivity after pharmacological noradrenergic stimulation in healthy controls. Labile noradrenergic responses, or increased sensitivity to norepinephrine, may increase risk for impulsive behavior.
RCT Entities:
RATIONALE: Rapid-response impulsivity, characterized by inability to withhold response to a stimulus until it is adequately appraised, is associated with risky behavior and may be increased in a state-dependent manner by norepinephrine. OBJECTIVE: We assessed effects of yohimbine, which increases norepinephrine release by blocking alpha-2 noradrenergic receptors, on plasma catecholamine metabolites, blood pressure, subjective symptoms, and laboratory-measured rapid-response impulsivity. METHODS: Subjects were 23 healthy controls recruited from the community, with normal physical examination and ECG, and negative history for hypertension, cardiovascular illness, and axis I or II disorder. Blood pressure, pulse, and behavioral measures were obtained before and periodically after 0.4 mg/kg oral yohimbine or placebo in a randomized, counterbalanced design. Metabolites of norepinephrine [3-methoxy-4-hydroxyphenylglycol (MHPG) and vanillylmandelic acid (VMA)] and dopamine [homovanillic acid (HVA)] were measured by high-pressure liquid chromatography with electrochemical detection. Rapid-response impulsivity was measured by commission errors and reaction times on the immediate memory task (IMT), a continuous performance test designed to measure impulsivity and attention. RESULTS:Yohimbine increased plasma MHPG and VMA but not HVA. Yohimbine increased systolic and diastolic blood pressure and pulse rate. On the IMT, yohimbine increased impulsive errors and impulsive response bias and accelerated reaction times. Yohimbine-associated increase in plasma MHPG correlated with increased impulsive response rates. Time courses varied; effects on blood pressure generally preceded those on metabolites and test performance. CONCLUSIONS: These effects are consistent with increased rapid-response impulsivity after pharmacological noradrenergic stimulation in healthy controls. Labile noradrenergic responses, or increased sensitivity to norepinephrine, may increase risk for impulsive behavior.
Authors: M Vythilingam; G M Anderson; M J Owens; T M Halaszynski; J D Bremner; L L Carpenter; G R Heninger; C B Nemeroff; D S Charney Journal: J Clin Endocrinol Metab Date: 2000-11 Impact factor: 5.958
Authors: M J Millan; A Newman-Tancredi; V Audinot; D Cussac; F Lejeune; J P Nicolas; F Cogé; J P Galizzi; J A Boutin; J M Rivet; A Dekeyne; A Gobert Journal: Synapse Date: 2000-02 Impact factor: 2.562
Authors: Alan C Swann; Daniel Birnbaum; Ashley A Jagar; Donald M Dougherty; F Gerard Moeller Journal: Biol Psychiatry Date: 2005-05-15 Impact factor: 13.382
Authors: Jim McBurney-Lin; Yina Sun; Lucas S Tortorelli; Quynh Anh T Nguyen; Sachiko Haga-Yamanaka; Hongdian Yang Journal: Neuropharmacology Date: 2020-05-21 Impact factor: 5.250
Authors: Katherine M Nautiyal; Kenji F Tanaka; Mary M Barr; Laurent Tritschler; Yannick Le Dantec; Denis J David; Alain M Gardier; Carlos Blanco; René Hen; Susanne E Ahmari Journal: Neuron Date: 2015-04-16 Impact factor: 17.173
Authors: Miranda L Groft; Marigny C Normann; Paige R Nicklas; Julia E Jagielo-Miller; Peter J McLaughlin Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2019-07-09 Impact factor: 3.000
Authors: M M Moran-Santa Maria; N L Baker; A L McRae-Clark; J J Prisciandaro; K T Brady Journal: Drug Alcohol Depend Date: 2016-02-23 Impact factor: 4.492
Authors: Anna Mueller-Schoell; Robin Michelet; Ferdinand Weinelt; Charlotte Kloft; Gerd Mikus Journal: Arch Toxicol Date: 2021-05-24 Impact factor: 5.153